Sevening Capital
七晟资本
Sevening Capital (七晟基金) is the venture capital arm of Chinese apparel conglomerate Septwolves (七匹狼), investing across hard tech and biotech. In the 2023-2025 window, it co-led or joined rounds in carbon-fiber composite maker Huayu New Materials (华渔新材料) , iPSC-derived neural cell drug developer Shize Biotech (士泽生物) alongside Sequoia China and Qiming Venture Partners , and power semiconductor firm SinoChips Technology (芯长征科技) in a Series D alongside TCL Ventures and Gaorong Capital . Its check sizes range from tens of millions to over 100 million RMB, typically as a co-investor rather than lead.
AI-generated — may contain errors, please verify.
Coverage
As the year draws to a close, five companies secure new funding to carry momentum into 2025 | FreeS Family Funding News Vol. 21
Looking forward to working alongside more outstanding founders.
峰瑞资本·Uncovering New Opportunities: Four Interdisciplinary Innovation Firms Announce Nine-Figure Funding Rounds | FreeS Family Funding News Vol.17
Looking forward to working alongside more outstanding founders.
峰瑞资本·SinoChips Technology Closes Hundreds of Millions of RMB in Series D Funding, Doubles Down on New Power Semiconductor Devices
Further increase R&D investment and capacity expansion in areas such as automotive and new energy.
高榕创投·
